These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33078630)

  • 1. Current treatment options and safety considerations when treating adult-onset Still's disease.
    Cavalli G; Farina N; Campochiaro C; Baldissera E; Dagna L
    Expert Opin Drug Saf; 2020 Dec; 19(12):1549-1558. PubMed ID: 33078630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult-onset Still's disease: Advances in the treatment.
    Castañeda S; Blanco R; González-Gay MA
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):222-238. PubMed ID: 27886796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult-onset Still's disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies.
    Efthimiou P; Kontzias A; Hur P; Rodha K; Ramakrishna GS; Nakasato P
    Semin Arthritis Rheum; 2021 Aug; 51(4):858-874. PubMed ID: 34175791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options.
    Bindoli S; Baggio C; Doria A; Sfriso P
    Drugs; 2024 Mar; 84(3):257-274. PubMed ID: 38441807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on the use of non-biological pharmacotherapy for adult-onset Still's disease.
    Di Cola I; Cipriani P; Ruscitti P
    Expert Opin Pharmacother; 2022 Oct; 23(14):1577-1587. PubMed ID: 36124816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anakinra for the treatment of adult-onset Still's disease.
    Castañeda S; Atienza-Mateo B; Martín-Varillas JL; Serra López-Matencio JM; González-Gay MA
    Expert Rev Clin Immunol; 2018 Dec; 14(12):979-992. PubMed ID: 30324816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
    Colafrancesco S; Manara M; Bortoluzzi A; Serban T; Bianchi G; Cantarini L; Ciccia F; Dagna L; Govoni M; Montecucco C; Priori R; Ravelli A; Sfriso P; Sinigaglia L;
    Arthritis Res Ther; 2019 Dec; 21(1):275. PubMed ID: 31829244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review).
    Junge G; Mason J; Feist E
    Semin Arthritis Rheum; 2017 Oct; 47(2):295-302. PubMed ID: 28757235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
    Gabay C; Fautrel B; Rech J; Spertini F; Feist E; Kötter I; Hachulla E; Morel J; Schaeverbeke T; Hamidou MA; Martin T; Hellmich B; Lamprecht P; Schulze-Koops H; Courvoisier DS; Sleight A; Schiffrin EJ
    Ann Rheum Dis; 2018 Jun; 77(6):840-847. PubMed ID: 29472362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
    Ruscitti P; Cipriani P; Liakouli V; Iacono D; Pantano I; Caso F; Perosa F; Atzeni F; Cantatore FP; Scarpa R; Ciccia F; Giacomelli R
    Rheumatol Int; 2020 Jan; 40(1):107-113. PubMed ID: 31263993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review on the use of biologics in adult-onset still's disease.
    Fautrel B; Patterson J; Bowe C; Arber M; Glanville J; Mealing S; Canon-Garcia V; Fagerhed L; Rabijns H; Giacomelli R
    Semin Arthritis Rheum; 2023 Feb; 58():152139. PubMed ID: 36442231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of biological agents in adult-onset Still's disease.
    Cavalli G; Franchini S; Aiello P; Guglielmi B; Berti A; Campochiaro C; Sabbadini MG; Baldissera E; Dagna L
    Scand J Rheumatol; 2015; 44(4):309-14. PubMed ID: 25656459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.
    Sfriso P; Bindoli S; Galozzi P
    Drugs; 2018 Aug; 78(12):1187-1195. PubMed ID: 30069732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adult-onset Still's disease].
    Dechant C; Krüger K
    Dtsch Med Wochenschr; 2011 Aug; 136(33):1669-73. PubMed ID: 21833888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.
    Reihl Crnogaj M; Čubelić D; Babić A; Mayer M; Anić B
    Rheumatol Int; 2020 Aug; 40(8):1317-1325. PubMed ID: 32506202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of abatacept in a refractory case of adult-onset Still's disease.
    Quartuccio L; Maset M; De Vita S
    Clin Exp Rheumatol; 2010; 28(2):265-7. PubMed ID: 20483052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease.
    Franchini S; Dagna L; Salvo F; Aiello P; Baldissera E; Sabbadini MG
    Arthritis Rheum; 2010 Aug; 62(8):2530-5. PubMed ID: 20506370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics for the treatment of adult-onset still's disease.
    Yoo DH
    Expert Opin Biol Ther; 2019 Nov; 19(11):1173-1190. PubMed ID: 31379214
    [No Abstract]   [Full Text] [Related]  

  • 19. Tocilizumab for the treatment of adult-onset Still's disease.
    Castañeda S; Martínez-Quintanilla D; Martín-Varillas JL; García-Castañeda N; Atienza-Mateo B; González-Gay MA
    Expert Opin Biol Ther; 2019 Apr; 19(4):273-286. PubMed ID: 30827128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab.
    Wawrzycki B; Krasowska D; Pietrzak A; Wielosz E; Majdan M; Lotti T
    Dermatol Ther; 2019 Sep; 32(5):e13041. PubMed ID: 31361930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.